Salary, Integrity and Selection of a New Chair for California’s $12 Billion Cell and Gene Therapy Enterprise
By David Jensen,
The California Stem Cell Report
| 05. 20. 2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is a person who is a pillar of integrity.
At least that is what a survey of the 35 board members showed today. The results were released this afternoon, less than one business day before the directors’ Governance Subcommittee takes up the matter of compensation and qualifications for the new chair.
The post carries a salary range that currently tops out at $566,500 annually. But that could be boosted by the directors of the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. Also figuring into the salary is whether the post should be a full-time job.
The new chair will oversee CIRM during the next decade or so, a period in which its results are likely to determine whether it lives or dies. Depending on its pace of spending, the agency will run out of cash... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...
